Use of Intravenous Ferric Carboxymaltose in Treatment of Anemia in Cancer Patients Undergoing Chemotherapy

Inclusion Criteria: * Patient is an adult more than or equal 18 years old at the time of informed consent. * Patient has pathologic diagnosis of solid tumor (breast cancer, colorectal, lung, sarcoma, head and neck, sarcoma, genitourinary or gynecological cancer). * Patients who started chemotherapy (with or without radiotherapy) or planned to receive chemotherapy for at least 12 weeks. * Patient has an Eastern Cooperative Oncology Group performance status between 0 and 2. * Patient with Hb ≤11 g/dL. * Patient has a Life expectancy at least 6 months. * Adequate hepatic and renal function defined as a serum aspartate aminotransferase or alanine aminotransferase level that are no more than 3 times the upper limit of the normal range, a serum bilirubin level that is no more than 2 times the upper limit of the normal range and a serum Creatinine level of less than 2 mg per deciliter. * Patient is able to understand and provide informed consent to participate in the study. Exclusion Criteria: * Patient has Hb \< 8.0 g/dL * Patient presenting with hematologic malignancy including * Prior gastric surgery. * Patients on definitive radiotherapy alone. * Patients with relevant history (within six weeks) or clinical evidence of hemolysis or active bleeding that could, in the investigator's judgment, be a potential cause for the anemia (no gross hematuria, hemoptysis, hematochezia or melena and negative stool for hemoccult) * Presence of other nutritional anemia; deficiency of vitamin B12 less than 187 pg/ml and deficiency of Folate less than 3.1 ng/ml according to the local laboratory normal ranges * Patient has Iron overload (Serum Ferritin more than 800 ng/ml or Transferrin saturation (TSAT) more than 40%) * Patient is pregnant or lactating. * Patient has a personal or family history of hemochromatosis. * Patient has hypersensitivity to any form of IV iron. * Patient has received red blood cells transfusion or used erythropoietin within 2 weeks of enrollment into the study. * Patient has received any form of intravenous iron within the last 12 weeks * Patient has received oral iron supplements within 1 month of enrollment to the study, except for multivitamin supplements containing less than 30 mg iron.